Breaking News, Financial News

Financial Report: Allergan

Loss in the quarter impacted by divestitures, lost exclusivity, and a decline in RESTASIS

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Allergan 4Q Revenues: $4.1 billion (-6%) 4Q Loss: $4.3 billion (earnings were $3.1 billion 4Q17) FY Revenues: $15.8 billion (-1%) FY Loss: $5.1 billion (loss of $4.1 billion FY17) Comments: Loss in the quarter was impacted by divestitures, products that lost exclusivity and a decline in RESTASIS (down 19% to $325 million) due to lower demand and net pricing, as well as the divestiture of the company’s Medical Dermatology business in September 2018. BOTOX Therapeutic (Neurosciences &am...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters